Shareholder meeting results

Summary by AI BETAClose X

BSF Enterprise PLC announced that all resolutions were passed by shareholders at its General Meeting, including authorities for directors to allot shares for specific and general purposes, and to disapply pre-emption rights. Following these approvals, an application has been made for the admission of 26,875,000 ordinary shares to the London Stock Exchange, comprising 25,000,000 placing shares and 1,875,000 fee shares, expected to be effective on June 12, 2026. Post-admission, the company's enlarged share capital will be 193,749,437 ordinary shares, representing the total voting rights.

Disclaimer*

BSF Enterprise PLC
08 June 2026
 

08 June 2026

BSF Enterprise PLC

 

Result of General Meeting

 

 

BSF Enterprise PLC (LSE: BSFA) ("BSF" or the "Company"), a leading innovator in tissue-engineered materials, is pleased to announce that at the Company's General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:

 

Resolution

Shares

 

For

% of votes

Against

% of votes

* Withheld

Ordinary Resolution:

1.   Directors' authority to allot shares for specific purposes

38,811,710

97.35%

1,057,257

2.65%

94

Ordinary Resolution:

2.   Directors' authority to allot shares for general purposes

38,358,885

97.30%

1,063,893

2.70%

446,283

Special Resolution:

3.   Disapplication of pre-emption rights for specific purposes

38,809,545

97.34%

1,059,422

2.66%

94

Special Resolution:

4.   Disapplication of pre-emption rights for general purposes

38,345,356

97.27%

1,077,422

2.73%

446,283

 

 

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" any of the Resolutions.

 

Following the passing of the Resolutions, an application has been made for 26,875,000 ordinary shares to be admitted to listing on the Equity Shares (transition) category of the Official List and to trading on the London Stock Exchange's main market for listed securities ("Admission") being 25,000,000 new ordinary shares pursuant to the Placing announced by the Company on 03 June in 2026 ("Placing Shares") and 1,875,000 new ordinary shares ("Fee Shares") in settlement of certain advisory fees.

 

It is expected that Admission of the Placing Shares and Fee Shares will become effective on or around 8.00 a.m. on 12 June 2026. 

 

Total Voting Rights

 

Following Admission, the Company's enlarged share capital will comprise 193,749,437 ordinary shares of 1 penny each. Therefore, the total number of voting rights in the Company will be 193,749,437. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
website here:

 

https://bsfenterprise.com/link/ejnLne 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Chairman

Che Connon - CEO & Director

 

We encourage all investors to share questions on this announcement via our investor website.

https://bsfenterprise.com/s/a1f22b

Bowsprit Partners

John Treacy

James Sheehan

 

 +44 (0)203 883 4430

ISIN of the Ordinary Shares

is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.

 

 

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings